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Abstract
The commitment of stem and progenitor cells toward specific hematopoietic lineages is
tightly controlled by a number of transcription factors that regulate differentiation programs
via the expression of lineage restricting genes. Nuclear factor one (NFI) transcription factors
are important in regulating hematopoiesis and here we report an important physiological
role of NFIX in B- and myeloid lineage commitment and differentiation. We demonstrate that
NFIX acts as a regulator of lineage specification in the haematopoietic system and the ex-
pression of Nfix was transcriptionally downregulated as B cells commit and differentiate,
whilst maintained in myeloid progenitor cells. Ectopic Nfix expression in vivo blocked early
B cell development stage, coincident with the stage of its downregulation. Furthermore, loss
of Nfix resulted in the perturbation of myeloid and lymphoid cell differentiation, and a skew-
ing of gene expression involved in lineage fate determination. Nfix was able to promote my-
eloid differentiation of total bone marrow cells under B cell specific culture conditions but not
when expressed in the hematopoietic stem cell (HSPC), consistent with its role in HSPC
survival. The lineage choice determined by Nfix correlated with transcriptional changes in a
number of genes, such as E2A, C/EBP, and Id genes. These data highlight a novel and criti-
cal role for NFIX transcription factor in hematopoiesis and in lineage specification.
Introduction
Hematopoietic stem cells (HSCs) give rise to lineage restricted progenitor cells of the myeloid,
lymphoid, and erythroid lineages through a series of commitment steps orchestrated by the ex-
pression of lineage restricting genes [1]. The nuclear factor one (NFI) protein family, also
known as NF-I and CTF (CAAT box transcription factor), act as transcriptional activators
and/or repressors of cellular and viral genes. In vertebrates, there are four closely related genes
named NFIA, NFIB, NFIC, and NFIX [2]. They encode for proteins with a conserved
N-terminal DNA-binding and dimerization domain and a C-terminal transactivation/repres-
sion domain, which exhibit a high variability due to extensive alternative splicing. NFI protein
family members act as homo- and heterodimers and bind with high affinity to the palindromic
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consensus sequence 50-PyTGGCA-N3-TGCCAPu-30. NFI binding motifs were detected in pro-
moters of genes expressed in different organs, including brain, lung, liver, intestine, muscle,
connective tissue, skeletal elements and hematopoiesis. Thus, NFI genes have distinct functions
depending on the cell type and target promoter context [2].
Recently Nfia was shown to regulate fate choice between erythrocytes and granulocytes in
CD34+ human hematopoietic cell specification [3]. Its expression was abrogated to allow ter-
minal granulocytic or monocytic differentiation via microRNA-223 and microRNA-424 re-
spectively and C/EBPalpha and PU.1 interactions [4,5] indicating that Nfia silencing is a
prerequisite for myelopoiesis. Furthermore, a transcriptome-wide approach revealed that Nfia
induces an eythroid transcriptional program in both CD34+ and leukaemic K562 cells [6]. Nfix
knockout mice die postnatally around p21 and have brain, intestine, and skeleton malforma-
tions [7,8] and Nfix deficient HSPCs fail to persist in long-term bone marrow engraftment
upon transplantation [9]. Recently Nfix was shown to be one of 36 regulatory factors with rela-
tively restricted expression in HSCs, that contributed towards converting a committed B cell to
a myeloid cell [10]. These data indicate that Nfi proteins may act as putative drivers of lineage
specification and perturbation.
In haematopoeitic cell maturation there are a number of transcription factors whose coordi-
nated action are responsible for lineage specification and differentiation. For example, Pax5
can transcriptionally activate a B cell program while directly suppressing alternate lineage spe-
cific genes (e.g. myeloid-erythroid and T) [11]. Pax5-/-, E2A-/-, EBF and FOXO1 mice have ar-
rested B cell development at the pro-B cell stage [12–15]. Indeed E2A-/- mice have reduced
HSCs with an increased proportion of cycling HSC and it was shown that E2A functions to
promote the developmental progression of the entire spectrum of early hematopoietic progeni-
tors [16,17]. Amongst other transcription factors known to play a role in myeloid and B lineage
fate, PU.1 and C/EBPalpha are critical. High levels of PU.1 enforce myeloid development while
low levels promote B cell differentiation [18]. In myeloid development, C/EBPalpha has a criti-
cal role in the commitment of mulitpotent progenitors into the myeloid lineage and knockout
mice have a block in the transition from common myeloid progenitors (CMP) to granulocyte-
macrophage progenitors (GMP) [19].
Here, we investigated the function of Nfix during hematopoietic differentiation and our
data support the role of Nfix as a regulator of lineage fate in the hematopoietic system. Nfix
modulated the differentiation of B cells and myeloid cells, effects that were seen in both overex-
pression and knockout systems. Nfix is transcriptionally downregulated as B cells differentiate
whereas its expression is maintained in myeloid progenitor cells. Loss of Nfix expression per-
turbs myelopoiesis and enhances B lymphopoiesis. Nfix-mediated lineage determination was
associated with transcriptional changes in a number of myeloid and lymphoid lineage specific
genes. These data highlight a novel role for Nfix transcription factor in hematopoietic cell fate.
Methods
Animals
All experiments were approved and performed in accordance with local and home office regu-
lations and the Experimental Animal Ethics Committees of University College Cork (B100/
4097) and University of Glasgow (60/4512). Nfix-/- mice and litter matched WT controls were
a gift from Richard Gronostajski.
Bioinformatic Analyses
Expression profiles of the B-cell progenitors (GSE11110) [20] and for the human hematopoiet-
ic stem and progenitor cells, terminally differentiated cells, and intermediate state cells
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(GSE24759)[21] were downloaded from the Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo/). Using GenePattern (Version3.3.3) the Affymetrix CEL files for the B-cell pro-
genitors were converted into a. gct file for analyses using the RMAmethod with quantile nor-
malisation and background correct. Analyses of these datasets were carried out using
GenePattern (Version3.3.3) and GraphPad Prism 5. GSEA was carried out using the GSEA
program suite (version 2.07) available from the Broad Institute (http://www.broadinstitute.org/
gsea/index.jsp) with gene sets obtained from the Molecular Signatures Database (MSigDB)
(version 3.0.).
Bone Marrow Transplant (BMT)
BMT experiments were performed as described previously. Briefly, 5FU (5mg) was adminis-
tered intravenously to 6–8wk old C57Bl/6 wild type mice (WT). 4 days later whole BM was iso-
lated, prestimulated overnight and retrovirally transduced ex vivo in the presence of IL-3
(10ng/ul), IL-6 (10ng/ul), and SCF (100ng/ul). Two 90 minute spinoculations were performed
24hours apart. 4 hours after the second spinoculation, 0.2–1x106 unsorted cells were trans-
planted into lethally-irradiated C57Bl/6 recipients and maintained on antibiotics for 2 wks
post-transplant. Engraftment was assessed by GFP expression in the peripheral blood 6 wks
post-BMT.
Cell Lines
32Dcl3 myeloid precursor cells and BA/F3 pro B cell lines [22] are both murine IL3-dependent
cell lines maintained in RPMI, 10% FBS, 1% Penicillin/Streptomycin and 1% L-Glutamine sup-
plemented with 10%WEHI conditioned media. OP9 stromal cells were kindly provided by J.C.
Zuniga-Pflucker [23] were maintained in αMEM, 20% FBS, 1% Penicillin/Streptomycin, 1%
L-Glutamine, 0.1% β-mercaptoethanol, 1% 100 mM sodium pyruvate and 1% HEPES (OP9
media).
Constructs and retroviruses
A 1203 bp fragment encoding the entire murine Nfix cDNA was subcloned (+/- N or C termi-
nus MYC tag) into pcDNA3.1/myc-HIS plasmid and MigR1 expressing GFP retrovirus.
Flow Cytometry and Cell Sorting
Cell suspensions were stained on ice after blocking with rat/mouse IgG in PBS/2% FBS. Cells
were sorted using a FACSAria-I (BDBiosciences) cell sorter. Analytical flow cytometry was per-
formed on a LSRII or BDFACs Canto II (BDBiosciences) and analyzed using FlowJo software
(Treestar). Cells were live gated using FSC/SSC, and single cells were analysed via FSC-H/FSC-
A gating. Stem and progenitor populations are described in S1 Table. All antibodies used were
obtained from eBioscience and are listed in S2 Table.
Methylcellulose clonogenic assays
For total BM colony assays, BM cells were isolated from a C57Bl/6 mouse, and retrovirally-
transduced with MigR1 and Nfix ex vivo in the presence of IL-3, IL-6, and SCF. Then, 20,000
GFP+ sorted cells were plated in triplicate in methylcellulose media (Methocult M3434; Stem-
Cell Technologies). For sorted populations total adult BM or FL cells from E14.5 mice were iso-
lated and sorted for HSPCs, LMPPs, CMPs, GMPs and CLPs and transduced with MigR1 or
Nfix then 24 hr later were plated at 5000 (HSPC), 25,000 (LMPP), 40,000 (CMP), 60,000
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(GMP) or 12,000 (CLP) in methylcellulose media. Colonies with>50 cells were scored and as-
sessed at 12–14 d.
OP9 cultures
FL was isolated from E14.5 C57Bl/6 embryos and a cell suspension was prepared. Cells were in-
cubated overnight in OP9 media supplemented with 20 ng/ml mSCF, 10 ng/ml IL6 and 10 ng/
ml IL3. Cells were then retrovirally-transduced with MigR1 or Nfix retrovirus. 24 hr post-
transduction these cells were either sorted for HSPCs and pro-B cells or plated without sorting
onto OP9 cells in complete MEMmedia supplemented with 5 ng/ml Flt3 and 1 ng/ml IL7.
Media was refreshed every 2 d and cells were replated to fresh OP9 cells every 4 d for 12–16 d,
at which point the cells were removed and stained in PBS with PerCPCy5.5-anti-B220, APC-
anti-CD19, AlexaFluor700-anti-CD11b, eFluor450-anti-Gr-1, biotinylated anti-CD45 (to ex-
clude OP9 cells) with streptavidin-PeCy7 secondary antibody. Cells were acquired on a LSRII
or BDFACS CantoII and analysed using FlowJo V7.6.5.
Quantitative RT-PCR
RNA was isolated from 32D and BA/F3 cells (transduced with control MigR1 or Nfix retrovirus
and sorted for GFP), and BM cells, using the RNEasy kit (Qiagen), then digested with DNaseI
and used for reverse transcription according to the manufacturer’s instructions (Superscript II
kit, Invitrogen). RT-PCR was performed on the ABI Prism 7900 sequence detection system
(Applied Biosystems). The ΔΔCT method was used to calculate the relative level of gene ex-
pression in each sample. High-throughput qPCR was performed on the 48.48 Dynamic Array
IFC system (Fluidigm). Primer sequences are listed in S3 Table. Specific target pre-amplifica-
tion was carried out. All reactions were carried out in triplicate. Expression levels of the target
genes were normalized relative to the mean of the reference genes ABL, GUSB, B2M and either
TBP and HPRT1, or ENOX2 and RNF20. Relative mRNA levels were calculated using the 2
-ΔΔCT method.
Results
Altered hematopoiesis in Nfix chimeric mice
To investigate a role for Nfix in haematopoietic cells, lethally-irradiated C57BL/6 mice were re-
constituted with retroviral control (MigR1) or Nfix expressing (MigR1-Nfix) vector transduced
hematopoietic progenitors. At 6–10 wk post bone marrow transplant (BMT), reconstitution
within the myeloid, B and T cell compartments was assessed in peripheral blood (PB). The per-
centage of both B220+ and CD19+ B cells was significantly reduced in the GFP+ population of
Nfixmice compared to MigR1 (Fig. 1A and B) whereas there was no change in the PB CD4+
and CD8+ T cell compartment (Fig. 1C). The reduction noted in the percentage of the B cell
compartment was complemented by a significant increase in the percentage of GFP+Gr-
1+CD11b+ myeloid cells in the periphery of Nfix chimeric mice (Fig. 1A and B). These data
suggest that enforced expression of Nfix results in the perturbation of peripheral myeloid and
B cell populations. A more pronounced effect was evident in the BM and spleen of Nfix chime-
ras (Fig. 2). The percentage of GFP+B220+CD19+ B cells was dramatically decreased in the BM
and spleen, whereas the percentage of GFP+Gr-1+CD11b+ myeloid cells was significantly in-
creased in the BM and spleen (Fig. 2A-C). Analysis of the GFP percentage in B cell and myeloid
populations in the periphery, BM and spleen revealed that the block in B cell and increase in
myeloid cells was likely due to the autonomous effect of Nfix expression in the cell and that the
defective B lymphopoiesis was not due to the myeloid hyperplasia (data not shown).
Nfix Expression Modulates B Lymphopoiesis and Myelopoiesis
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Nfix expression decreases during B cell development
As we saw a block in the development of B220+CD19+ B cells in the BM, spleen and PB, we
sought to determine the endogenous expression of Nfix during B lymphopoiesis. We analysed
the publically available microarray dataset of mouse B cell lineage populations accessed
through the GEO database [20]. This dataset included hCD25- and hCD25+ CLP
(Lin-B220-CD19-CD127+Flt3+Sca1lowKitlow)(hCD25 under the control of the B-lineage re-
stricted Igll1 promoter), pro-B (CD19+AA4.1+CD43low), pre-B (CD19+B220+CD43-IgM-) and
mature spleen (IgM+CD19+) B cells. Endogenous Nfix expression was dramatically reduced at
the pro-B cell stage of B lymphopoiseis compared to the CLP populations, and further de-
creased as the B cells differentiate to pre-B and mature spleen B cells (Fig. 3A). We next per-
formed qRT-PCR on B cell progenitor fractions sorted fromWT C57Bl/6 mice. NfixmRNA
expression was assessed in pre-pro B (B220+CD43+CD19-), pro-B (B220+CD43+CD19+), pre-B
(B220+CD43-CD19+IgM-), and immature B (B220+CD43-CD19+IgM+). Consistent with the
microarray analysis, Nfix expression decreased after the pre-pro-B cell stage and continued to
decrease to the immature B cell stage (Fig. 3B). As a control, gene expression analysis of lineage
specific transcription factors in the microarray dataset and in mRNA from sorted murine pop-
ulations revealed consistent results (S1 Fig.). We next assessed whether this pattern of NFIX ex-
pression was evident in human B cell subsets. Using the microarray dataset from human cell
compartments accessed through the GEO database [21] we assessed NFIX expression in the
HSC2 (Lin-CD38-CD34+), early B-cell (CD34+CD10+CD19+) and pro-B cell
(CD34-CD10+CD19+) compartments. There was a decrease in NFIX expression from the
HSC2 compartment of human cells to the pro-B cell compartment (Fig. 3C). NfixmRNA ex-
pression was further assessed in HSPC through to myeloid progenitor populations (HSPC
Fig 1. Decreased B cells and increasedmyeloid cells inNfix expressing cells in the periphery. C57Bl/6 mice were reconstituted with BM cells
transduced with control MigR1 or Nfix vectors. (A)Graph of percentage number of GFP+ B cells (B220+, CD19+), myeloid cells (Gr-1+CD11b+), and (C) T
cells (CD4+, CD8+) in the PB of MigR1 andNfix chimeric animals 6 weeks post-transplant. (B) Representative flow cytometric analysis of PB cells in MigR1
andNfix chimeric animals, 10 wk post-transplant, showing engraftment of GFP (left panel), B220+CD19+ B cells in the GFP- and GFP+ fractions (middle
panel, percentages given) and the Gr-1+CD11b+ myeloid cells in the GFP- and GFP+ fractions (right panels, percentages given). Results are representative
of 2 independent BMT experiments.
doi:10.1371/journal.pone.0120102.g001
Nfix Expression Modulates B Lymphopoiesis and Myelopoiesis
PLOS ONE | DOI:10.1371/journal.pone.0120102 March 17, 2015 5 / 15
(Lin-cKit+Scat1+Flt3-), LMPP (Lin-cKit+Scat1+Flt3+), CMP (Lin-cKit-CD34intCD16/32int),
GMP (Lin-cKit-CD34+CD16/32+) and MEP (Lin-cKit-CD34loCD16/32lo)). Nfix expression was
not downregulated in myeloid restricted progenitor populations (Fig. 3D). We observed simi-
larities in NFIX expression using HemaExplorer platform (data not shown) [24]. These data
show that NFIX expression decreased during both murine and human B cell lineage differenti-
ation. To further support this, a detailed B cell development flow cytometric analyses was per-
formed in Nfix chimeras in vivo. Consistent with our bioinformatics analyses showing a
decrease in Nfix expression at the early stages of B cell stage of development, we saw an accu-
mulation of the early B cell marker CD43 (which is normally turned off at the pre-B cell stage)
and B220loCD43+ cells, and a concomitant decrease in the percentage of B220hi and CD43- B
cells in Nfix chimeric animals as compared to MigR1 controls (Fig. 3E and F). These data dem-
onstrate that ectopic expression of Nfix resulted in a block in early B-cell development in vivo,
consistent with the stage when endogenous Nfix is downregulated.
Nfix expression favors myelopoiesis over B cell lymphopoiesis
To further investigate the block in B cell and increase in myeloid cell development we observed
in vivo, we carried out in vitro differentiation assays using the BM stromal OP9 cell line that
supports B and myeloid cell development depending on the cytokines used. Unsorted E14.5
fetal liver (FL) cells were retrovirally transduced with MigR1 or MigR1-Nfix and cultured on
Fig 2. Decreased B cells and increasedmyeloid cells inNfix expressing cells in the bonemarrow and
spleen.C57Bl/6 mice were reconstituted with BM cells transduced with control MigR1 or Nfix vectors. Graph
of percentage of B cells (left, B220+CD19+) and myeloid cells (right, Gr-1+CD11b+) in the (A) BM and (B)
Spleen of MigR1 andNfix chimeric animals (GFP+) 10 wks post-transplant. Representative flow cytometric
analysis in MigR1 and NFIX chimeric animals, 10 wk post transplant, showing GFP engraftment (left panel),
B220+CD19+ B cells (middle panel, percentages given) and Gr-1+CD11b+ myeloid cells (right panel) in the
GFP- and GFP+ fractions of the bone marrow (C) and spleen (D). Results are representative of 2 independent
BMT experiments.
doi:10.1371/journal.pone.0120102.g002
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OP9 cells supplemented with 5 ng/ml FLT3 and 1 ng/ml IL7 to support B cell development.
MigR1 expressing control FL cells robustly developed B cells after 16 days co-culture whereas
in contrast, Nfix expressing FL cells were unable to develop B220+CD19+ B cells. Furthermore,
Nfix expressing FL cells efficiently differentiated into CD11b+Gr-1+ myeloid cells in this sys-
tem, despite being in the presence of B cell permissive cytokines (Fig. 4A and B). GFP percent-
ages throughout the culture revealed that as B cells differentiate in this culture, the GFP
percentage declines (S2A Fig.). To determine whether Nfix expression could drive myelopoiesis
and block B lymphopoiesis from HSPCs (Lin-Sca1+cKit+Flt3-), we retrovirally transduced puri-
fied FL-HSPC with MigR1 and Nfix and cultured on OP9 cells supplemented with 5 ng/ml
FLT3 and 1 ng/ml IL7. Nfix overexpression in purified HSPCs abrogates B cell development in
this OP9 culture system (Fig. 4C and D, S2B Fig.). Nfix overexpression is however not toxic to
committed pro B cells, as BA/F3 cells overexpressing Nfix do not have any evidence of altered
cell growth, proliferation or apoptosis (S2C–G Fig.). To assess the molecular changes involved
in the perturbation of lineage specificity in Nfix expressing cells, we carried out gene expression
analysis on a number of lineage specific targets (Fig. 4E and S3 Table). It has been proposed
that upregulation of ID genes and subsequent E-protein inhibition are involved in myeloid
lineage commitment while shutting off the lymphoid fate as cells transit from the LMPP com-
partment [25]. Our analysis showed that ectopic Nfix expression in BM cells led to significant
Fig 3. Nfix expression in stem and progenitor populations. (A) Analysis of Nfix expression during murine B cell differentiation using the B-cell lineage
microarray dataset (GSE11110)[41]. Error bars represent max and minNfix expression values. (B)Quantitative RT-PCR analysis of Nfix expression in
murine B cell populations fractionated by flow cytometry. Data are representative of three independent experiments, performed in duplicate. Error bars
denote ±SD. (C) Analysis of NFIX expression in human B cell development from the human hematopoiesis microarray dataset (GSE24759) (21). Plots
represent raw values, error bars represent max and min values. (D) Analysis of Nfix expression by qRT-PCR in murine stem and progenitor cells isolated
from bone marrow. (E)Graph of percentage expression of CD43+, B220+, and B220loCD43+ populations in BM cells from chimeras established with MigR1
or Nfix progenitors 8–10 wks previously. Error bars denote +/- SD of 2 independent experiments (n = 3). (F) Representative flow cytometric analysis, with
gates and percentages showing B220loCD43+ populations (early B cells) in GFP- and GFP+ populations.
doi:10.1371/journal.pone.0120102.g003
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decrease in E2A, and concomitant increase in ID2 and ID3 (Fig. 4C). These gene expression
changes correlate with the Nfix-mediated lineage perturbations in vitro and in vivo.
Myeloid differentiation was further investigated by plating MigR1 and Nfix expressing total
BM cells, and purified HSPCs, CMP and GMP populations (immunophenotype markers in
supplementary methods) in methylcellulose media that supports optimal growth of erythroid
progenitors (BFU-E), granulocyte-macrophage progenitors (CFU-GM, CFU-M, CFU-G) and
multi-potential granulocyte, erythroid, macrophage, megakaryocyte progenitors (CFU-
GEMM) cells (M3434 methocult). Nfix overexpression in bulk BM cells did not change total
colony number or the number of cells per colony type. However there is a clear trend towards
lower numbers of immature NFIX derived colonies compared with MigR1 (CFU-E and CFU-
GEMM) with a concomitant increase in more mature myeloid colonies (CFU-GM and CFU-
G) (Fig. 5A). This was evident by an increase in CD11b and F4/80 marker expression detected
by flow cytometry (Fig. 5B). In HSPCs, there was no significant difference in the number of
Fig 4. Nfix blocks B cell differentiation in vitro in favour of myelopoiesis. (A) Total FL was transduced
with control MigR1 or Nfix, plated on OP9 cells and analyzed by flow cytometry on day 16. FACS plots of
GFP+ B cells (B220+CD19+, top panels) and GFP+ myeloid cells (CD11b+Gr-1+, lower panels) representative
of 3 replicates from 2 independent experiments. (B)Graph of average percentage of B220+CD19+ (left) and
CD11b+Gr-1+ (right) from (A). Error bars denote +/- SD of 2 independent experiments (n = 3). Graph shows a
statistically significant decrease in Nfix derived B220+CD19+ cells (p = 0.02) and a significant increase inNfix
derived CD11b+Gr-1+ cells (p = 0.01) when compared with MigR1 controls. (C) E14.5 FL HSPCs
(Lin-Sca1+cKit+Flt3-) transduced with control MigR1 or Nfix retrovirus were plated on OP9 cells (Day 0) and
analysed by flow cytometry on day 12 with FACs plots of GFP expression (left histograms) and GFP- and
GFP+ B220+CD19+ cells (right dot plots) representative of 2 independent experiments. (D)Graph of average
percentage of B220+CD19+ cells from (C), error bars denote +/- SD of 2 independent experiments.
Experiment shows significant decrease in Nfix expressing B cells compared with control MigR1 (p = 0.01) (E)
Total BM cells were sorted for MigR1 andNfix expression 24 hr post transduction and qRT-PCRwas
performed. Graphical presentation of relative mRNA expression of Nfix, E2A, ID2 and ID3 genes and
presented relative to control MigR1 cells. Error bars denote +/- SD of 3 technical replicates. Data
representative of 2 biological replicates.
doi:10.1371/journal.pone.0120102.g004
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colonies derived from Nfix expressing HSPCs when compared with control, however, there
was a significant decrease in the number of colonies formed from CMP and GMP cells express-
ing Nfix (Fig. 5C). Flow cytometric analysis of the colonies following 12–14 days in culture re-
vealed a pronounced increase in the number of CD11b+ and F4/80+ cells (markers of mature
myeloid cells) in CMP and GMP colonies when compared with control (Fig. 5D). The decrease
in colony number and in increase CD11b+ and F4/80+ indicate that Nfix drives mature myeloid
Fig 5. Efficient differentiation of myeloid cells inNfix expressing cells. (A)MigR1 andNfix transduced
total BM cells were plated in methylcellulose media (M3434) and colonies scored after 9–11 days according
to morphological criteria. The mean percentage of erythroid (E), granulocyte/erythrocyte/monocyte/
megakaryocyte (GEMM), granulocyte/monocyte (GM) macrophage (M) and granulocyte (G) colonies are
shown from 3 independent experiments +/- SEM. A statistically significant decrease in CFU-EE colonies
indicated. (B) Representative flow cytometric analysis of total cells from colony assay in (A). (C)Graph of
methylcellulose colony numbers from HSPCs, CMPs and GMPs sorted and transduced with control MigR1 or
Nfix. Colonies were counted on day 12 and graph represents mean of triplicate plates normalized to GFP
expression +/- SD. (D) Representative flow cytometric analysis of cells from colony assay in (C). 32D cells
transduced with MigR1 or Nfixmaintained in either IL3 (E) or G-CSF (F) for 5 days, and analyzed for F4/80
expression by flow cytometry. The mean percentages of 3 independent experiments are shown +/- SD. (G)
32D cells and (H) Ba/F3 cells transduced with MigR1 andNfix and qRT-PCR performed. Graphical
presentation of relative mRNA expression ofNfix, MMP9, G-CSFr and C/EBPalpha genes and presented
relative to control MigR1 cells. Error bars denote +/- SD of 3 technical replicates. Data representative of 2
biological replicates.
doi:10.1371/journal.pone.0120102.g005
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differentiation and these effects are pronounced at the CMP stage of development. To further
support the role of Nfix in myeloid lineage differentiation, we expressed Nfix in the IL-3 depen-
dent 32D myeloid cell line and assessed the effect on myeloid cell surface differentiation mark-
ers. There was a statistically significant increase in myeloid differentiation as assessed by the
expression of F4/80 in the presence of IL3 alone upon Nfix expression, which was further en-
hanced in the presence of the myeloid-permissive cytokine G-CSF (Fig. 5E and F). Gene ex-
pression analysis of 32D and BA/F3 sorted for Nfix expression revealed that Nfix significantly
increased the expression of the myeloid specific genes C/EBPalpha and target gene GCSF-R
and MMP9 (Fig. 5G and H). These data strongly suggest that ectopic expression of Nfix in
vitro and in vivo biases hematopoietic progenitors to the myeloid lineage and suppresses
lymphoid development.
Loss of Nfix expression promotes B lymphopoiesis while impairing
myelopoiesis
To investigate the physiological relevance of Nfix in myeloid and lymphoid lineage specifica-
tion, we isolated BM from Nfix-/- neonate mice and cultured it on OP9 cells. There was a
marked increase in cells expressing B220 after 4 and 6 days in culture compared with WT litter-
mate control cells (Fig. 6A-C). Myeloid differentiation of Nfix deficient cells was assessed in
methylcellulose colony assays. Nfix deficient BM cells formed significantly fewer colonies than
their WT counterparts (Fig. 6D), and expressed significantly lower percentages of mature mye-
loid markers CD11b, Gr1 and F4/80 (Fig. 6D-F). These data indicate that loss of Nfix perturbs
normal myeloid differentiation. Gene expression analysis by qRT-PCR reveals that Nfix defi-
cient BM cells have a marked disruption in the expression of key transcription factors involved
in lineage fate determination (Fig. 6G). Of particular interest is the downregulation of Id genes
and MMP9 (the inverse of our overexpression data), and an upregulation of CD19 and Pu.1 in
Nfix deficient cells, supporting a role of Nfix in cell lineage fate. Taken together, these loss of
function data show that loss of Nfix in the BM leads to altered hematopoiesis by enhancing B
cell development while disrupting myelopoiesis, and that this effect is mediated by changes in
key transcription factors associated with lineage fate determination.
Discussion
We report an important role of the transcription factor Nfix in hematopoietic cell fate, specifi-
cally in B- and myeloid lineage differentiation. Our studies indicate that Nfix expression is
downregulated as the cells become committed to the B cell lineage, and loss of Nfix expression
enhances B cell lineage fate, concomitant with skewed myelopoiesis and altered expression of
lineage fate genes. Enforced Nfix expression prevents early B cell development and favors mye-
loid differentiation in vitro and in vivo which correlates with an alteration in lineage-specific
commitment genes of the B and myeloid lineages.
We noted higher NfixmRNA expression in the early B cell progenitor populations in both
mouse and human hematopoietic cells and downregulation of its expression as cells commit
and mature to the B cell lineage. Our data shows that upon ectopic expression of Nfix in vivo,
B cell development is severely impaired in the BM and spleen of chimeric animals. Although
some CD19+B220+ B cells were still present in the spleen of Nfix chimeric animals, there was
almost complete block in CD19+B220+ B cell production in the BM. These data suggest that
upon continued expression of Nfix, B cell development in the BM is impaired. In accordance
with the downregulation in NfixmRNA expression to pro-B cell stage of differentiation, accu-
mulation of B220loCD43+ early B cells in the BM of Nfix chimeric animals was observed. Addi-
tionally, using the in vitroOP9 co-culture system, enforced Nfix expression in the HSPC
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compartment led to an almost complete absence of Nfix expressing cells at the end of the cul-
ture period. The very small percentage of surviving Nfix expressing cells derived from HSPCs
do not express CD19 yet do express B220lo consistent with the block at an early stage of devel-
opment seen in vivo. Nfix surviving cells were observed when the transduced population in-
cluded more myeloid committed progenitors even when cultured on OP9 cells in B cell
cytokine conditions. In this case, Nfix expressing cells were of the myeloid lineage. The fact
that this culture system contained no myeloid specific cytokines and generates an environment
that efficiently produces B cells as seen by control cultures, provides strong evidence that Nfix
has a functional role in lineage fate.
Transcriptional lineage priming of hematopoietic stem and progenitor cells has been shown
to define their lineage potential [26]. The commitment of hematopoietic progenitors to the B
cell lineage and their development to mature B cells depends on the combined activities of the
transcription factors E2A, EBF, and Pax5 [27]. The earliest B cell progenitors express a lineage
restricted marker B220, together with CD43 [28]. The progenitors are mostly B lineage com-
mitted, even in the absence of detectable CD19 surface expression (27) and PAX5 [29]. E
Fig 6. Loss ofNfix perturbs myelopoiesis while driving B cell differentiation. Total BM fromWT or Nfix
deficient mice was plated onto OP9 cells and analysed by flow cytometry on day 4 (A) and day 6 (B). Bar
chart shows the mean percentages of B220+ cells from 3 independent experiments +/- SD. (C)
Representative flow cytometric analysis of cells expressing B220 at day 6. (D) Total BM fromWT or Nfix
deficient mice was plated in methylcellulose (M3434). Colonies were counted after 11 days. Bar chart
represents the mean number of colonies from 2 independent experiments +/- SD. (E) Bar chart shows the
mean percentages of Gr1 + and F4/80+ cells from 2 independent experiments +/- SD. (F) Representative flow
cytometric analysis of cells from colony assay which were stained with Gr-1 and F4/80. (G)Graphical
presentation of relative mRNA expression of indicated genes assessed using high-throughput qPCR on the
48.48 Dynamic Array IFC system (Fluidigm). Bars represent the average of 3 biologicalNfix-/- replicates
normalized to WT control, and error bars denote +/- SD.
doi:10.1371/journal.pone.0120102.g006
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proteins are well known to be crucial for lymphopoiesis [14] however recently it was shown
that HSCs and LMPPs from E2A-/- mice show an increase in proliferation accompanied by effi-
cient myeloid- but not lymphoid cell differentiation [16]. Indeed, E2A-deficient HSCs fail to
maintain the HSC pool and the entire spectrum of early hematopoietic progenitors [17]. E-pro-
teins are antagonized by the Id proteins, which contain an HLH motif but lack a DNA binding
region [30]. Furthermore, it has been documented that the downregulation of both Id2 and Id3
is an essential event in B-lineage specification although the loss of either factor was not suffi-
cient to promote B cell development [31]. We observed significant changes in E2A, Id2 and Id3
in Nfix-deficient cells and upon ectopic Nfix expression. This perturbation in the levels of E2A
and Id gene expression are consistent with a block in B cell lineage commitment and differenti-
ation and the efficient myeloid cell production observed. The modulation of Id expression can
induce a reversal of B lineage commitment [32] and Id-mediated inhibition of E proteins was
shown to be involved in myeloid lineage commitment [25] suggesting that the balance between
Id and E proteins regulates myeloid-versus-lymphoid lineage decisions.
Cell fate decisions during hematopoiesis are governed by lineage-specific transcription fac-
tors e.g. PU.1 and C/EBP family members. PU.1 transcription factor has a well-documented
central role controlling myeloid and early B and T-cell development and PU.1 expression levels
are important in the determination of lineage fate [33,34]. Recently it was shown that PU.1 ex-
pression is regulated differentially in B cells and myeloid cells through differential association
with cell-type specific transcription factors and a balance of sense and antisense RNAs at one
of its upstream regulatory elements [35,36] and through cell cycle duration effects [37]. The
modulation of PU.1 seen in Nfix-deficient cells is consistent with the role of PU.1 in myeloid
versus B lineage cell fate. It has previously been shown that CEBPA loss-of-function mutations
decrease myeloid priming of HSCs while simultaneously impairing myeloid-lineage commit-
ment [38]. In addition, C/EBPs are known to be regulated by Runx1 [39] and to positively reg-
ulate PU.1 expression [40] in myeloid lineage fate choices. A recent study identified 36 factors
that could reprogram a committed B cell into a myeloid cell and Nfix was one of these factors
[10]. Our data show that alone, Nfix can modulate the fate of a stem and progenitor cell toward
the B and myeloid lineage. Nfix can thus be hypothesized to act as a molecular switch involved
in lineage instruction and commitment. Whether this occurs due to lineage priming in the
stem cell compartment or due to antagonistic or synergistic activity in a committed progenitor
cell is not yet known.
The data presented here indicate that the failure to downregulate Nfix would be detrimental
to B cell production and favor myelopoiesis. Collectively, these data suggest that Nfix expres-
sion at early stages of development (HSPCs) can modulate the myeloid-versus-lymphoid diver-
gent cell fate, potentially via the direct modulation of downstream transcriptional targets.
Supporting Information
S1 Fig. Gene expression in human and murine B cell progenitor populations. (A) B-cell and
myeloid cell gene expression in the B-cell progenitor microarray data. Max gene expression
data was calculated for each B-cell progenitor population from the B-cell progenitor microar-
ray dataset (GSE11110). Microarray data was collapsed to max probe expression for each gene
using the Collapse Dataset suite in GenePattern. Values for each progenitor cell type were then
plotted using GraphPad. Error bars represent max and min values for each cell type. (B) Quan-
titative RT-PCR analysis of B cell and myeloid cell specific gene expression in sorted murine B
cell populations fractionated by flow cytometry. Relative levels of CEBPA, Il7R, NOTCH1,
PAX5, SFPI1, EBF1, CD19 and BLNK expression in pre-pro, pro, pre and immature B cell pop-
ulations. 18S was used as an endogenous control. Each gene/18s ratio in pre-pro B cell
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progenitors was normalized to 1.
(TIF)
S2 Fig. Ectopic Nfix expression does not effect cell growth or viability but in B cell growth
conditions BM cells expressing Nfix are lost over time. (A) Tracking GFP expression in
MigR1 and Nfix expressing total FLCs over 16 days in culture. Graph represents the average
+/- SD of 2 independent experiments (3 technical replicates). (B) Graph of the average GFP ex-
pression in MigR1 and Nfix expressing FLC HSPCs after 0 and 12 days in OP9 co-culture.
Error bars denote +/-SD of 2 biological replicates. (C) Tracking GFP expression in MigR1 and
Nfix expressing BaF/3 cells over 5 days in culture, showing mean of 3 technical replicates +/-
SD. Graph is representative of 2 independent experiments. (D) Graph of 5 days of cell growth
of GFP sorted BaF/3 cells transduced with either MigR1 or Nfix. Each point represents the av-
erage number of cells from 2 independent experiments. Error bars denote +/- SD. (E) Tracking
Baf/3 cell division after 5 days in culture as shown by dilution of Cell Trace Violet in GFP ex-
pressing cells. MigR1 and Nfix overexpressing cells are compared to unstained control and Day
0 cells as positive and negative controls respectively. Graph is representative of 2 independent
experiments. (F) Representative FACs plot of the expression of apoptotic markers AnnexinV
and DAPI in MigR1 or Nfix transduced, GFP sorted BaF/3 cells, 4 days after transduction. (G)
Graph of the average percentage of GFP sorted BaF/3 cells expressing DAPI, AnnexinV and
live cells (double negative for DAPI and AnnexinV), from 2 independent experiments. Error
bars denote +/- SD.
(TIF)
S1 Table. Sorting stem and progenitor populations.
(PDF)
S2 Table. FACs Antibodies (eBioScience).
(PDF)
S3 Table. Primer Sequences (rtPCR & Fluidigm).
(PDF)
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